
EXEL
Healthcare · Biotechnology · $16.84B market cap
$69.00-0.84 (-1.2%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +11.2% over 90 days · 30-day revisions 6 up, 0 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Oct 29, 2026 | After the close | 0.79 | 0.85 | +7.6% |
| Aug 5, 2026 | After the close | 0.75 | 0.82 | +9.3% |
| May 5, 2026 | After the close | 0.76 | 0.87 | +14.5% |
| Feb 10, 2026 | After the close | 0.81 | 0.94 | +16.0% |
| Nov 4, 2025 | After the close | 0.67 | 0.78 | +16.4% |
| Jul 28, 2025 | After the close | 0.65 | 0.75 | +15.4% |
| Apr 28, 2025 | Before the open | 0.37 | 0.62 | +69.1% |
| Feb 11, 2025 | After the close | 0.49 | 0.55 | +12.2% |
| Oct 29, 2024 | After the close | 0.42 | 0.47 | +11.9% |
| Aug 6, 2024 | After the close | 0.37 | 0.84 | +127.0% |
| Apr 30, 2024 | After the close | 0.29 | 0.17 | -41.4% |
| Feb 6, 2024 | After the close | 0.31 | 0.33 | +6.5% |
| Nov 1, 2023 | After the close | 0.19 | 0.10 | -47.4% |
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its…
| Aug 1, 2023 | After the close | 0.22 | 0.31 | +40.9% |
| May 9, 2023 | After the close | 0.22 | 0.16 | -27.3% |
| Feb 7, 2023 | After the close | -0.05 | -0.03 | +40.0% |
| Nov 1, 2022 | After the close | 0.24 | 0.31 | +29.2% |
| Aug 9, 2022 | After the close | 0.24 | 0.28 | +16.7% |
| May 10, 2022 | After the close | 0.23 | 0.26 | +13.0% |
| Feb 17, 2022 | After the close | 0.16 | 0.35 | +118.8% |
| Nov 2, 2021 | After the close | 0.27 | 0.20 | -25.9% |
| Aug 5, 2021 | After the close | 0.14 | 0.37 | +164.3% |
| May 6, 2021 | After the close | 0.09 | 0.09 | 0.0% |
| Feb 10, 2021 | After the close | 0.10 | 0.14 | +40.0% |
| Nov 5, 2020 | After the close | 0.04 | 0.04 | 0.0% |
| Aug 6, 2020 | After the close | 0.14 | 0.25 | +78.6% |
| May 5, 2020 | After the close | 0.17 | 0.19 | +11.8% |
| Feb 25, 2020 | After the close | 0.17 | 0.22 | +29.4% |
| Oct 30, 2019 | After the close | 0.22 | 0.34 | +54.5% |
| Jul 31, 2019 | After the close | 0.28 | 0.29 | +3.6% |
| May 1, 2019 | After the close | 0.24 | 0.24 | 0.0% |
| Feb 12, 2019 | After the close | 0.23 | 0.37 | +60.9% |
| Nov 1, 2018 | After the close | 0.17 | 0.41 | +141.2% |
| Aug 1, 2018 | After the close | 0.16 | 0.28 | +75.0% |
| May 2, 2018 | After the close | 0.15 | 0.37 | +146.7% |
| Feb 26, 2018 | After the close | 0.12 | 0.12 | 0.0% |